Cargando…

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis

BACKGROUND/AIMS: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy of a new vedolizumab subcutaneous (SC) formulation. METHODS: Eligible patients received open-label...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Taku, Ito, Hiroaki, Ashida, Toshifumi, Yokoyama, Tadashi, Nagahori, Masakazu, Inaba, Tomoki, Shikamura, Mitsuhiro, Yamaguchi, Takayoshi, Hori, Tetsuharu, Pinton, Philippe, Watanabe, Mamoru, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566830/ https://www.ncbi.nlm.nih.gov/pubmed/32806876 http://dx.doi.org/10.5217/ir.2020.00026

Ejemplares similares

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
por: Okamoto, Hiroyuki, et al.
Publicado: (2021)

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
por: Watanabe, Kenji, et al.
Publicado: (2019)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
por: Fenu, Elisabetta, et al.
Publicado: (2022)

Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study
por: Nagahori, Masakazu, et al.
Publicado: (2017)

Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Performing colonoscopy before steroid induction is associated with shorter steroid use in patients with ulcerative colitis
por: Kobayashi, Taku, et al.
Publicado: (2023)

Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2018)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
por: Schultz, Bob G, et al.
Publicado: (2021)

Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis
por: Hu, Qiong, et al.
Publicado: (2023)

Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis
por: Kobayashi, Taku, et al.
Publicado: (2019)

Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network)
por: Yamazaki, Hajime, et al.
Publicado: (2019)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy
por: Meeralam, Yaser, et al.
Publicado: (2023)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Tacrolimus for the Treatment of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2015)

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized study
por: Ito, Hiroaki, et al.
Publicado: (2010)

Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized study
por: Ito, Hiroaki, et al.
Publicado: (2010)

Improving IBD outcomes in the era of many treatment options
por: Kobayashi, Taku, et al.
Publicado: (2023)

A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis
por: Kobayashi, Taku, et al.
Publicado: (2017)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
por: Oki, Yusuke, et al.
Publicado: (2023)

Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
por: Kothari, Megha, et al.
Publicado: (2015)

Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
por: Subhaharan, Deloshaan, et al.
Publicado: (2022)

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
por: Hibi, Toshifumi, et al.
Publicado: (2019)

Development of algorithms for identifying patients with Crohn’s disease in the Japanese health insurance claims database
por: Morikubo, Hiromu, et al.
Publicado: (2021)

Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
por: Hibi, Toshifumi, et al.
Publicado: (2020)

2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Inflammatory Bowel Disease in Japan -Is It Similar to or Different from Westerns?-
por: Okabayashi, Shinji, et al.
Publicado: (2020)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

New and emerging treatments for ulcerative colitis: a focus on vedolizumab
por: Gledhill, Tamsin, et al.
Publicado: (2013)

Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
por: Singh, Amrinder, et al.
Publicado: (2022)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
por: Kobayashi, Taku, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aqth05hnnahajk0jbccmjrsf9b